

**In the Claims:**

The following listing of claims will replace any/all prior versions, and listings, of claims in the application:

Claims 1-40 (Cancelled).

Claim 41 (Currently Amended) A method of treating or preventing a nervous system disorder fibromyalgia and other somatoform disorders, the method comprising the step of administering a therapeutically effective dose of racemic reboxetine or a pharmaceutically acceptable salt thereof to an individual, ~~wherein said disorder is selected from the group consisting of at least one of an adjustment disorder, an age-associated learning and mental disorder, anorexia nervosa, apathy, an attention deficit disorder due to general medical conditions, bipolar disorder, bulimia nervosa, chronic fatigue syndrome, chronic or acute stress, chronic pain, cyclothymic disorder, dysthymic disorder, fibromyalgia and other somatoform disorders, incontinence, mania, migraine headaches, obesity, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder, seasonal affective disorder, a sleep disorders, a specific developmental disorders, SSRI "poop out" syndrome, and TIC disorders .~~

Claim 42 (Cancelled).

Claim 43 (Cancelled).

Claim 44 (Original) The method of claim 41 wherein the reboxetine is administered to the individual in an amount of about 2 to about 20 mg/day.

Claim 45 (Original) The method of claim 44 wherein the reboxetine is administered to the individual in an amount of about 4 to about 10 mg/day.

Claim 46 (Original) The method of claim 45 wherein the reboxetine is administered to the individual in an amount of about 6 to about 10 mg/day.

Claim 47 (Original) The method of claim 41 wherein said reboxetine is administered orally, parenterally, topically, transdermally, rectally, or vaginally.

Claim 48 (Original) The method of claim 47 wherein said reboxetine is orally administered with a pharmaceutically acceptable carrier comprising at least one of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, and wetting agent.

Claim 49 (Original) The method of claim 48 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim 50 (Original) The method of claim 47 wherein said reboxetine is parenterally administered subcutaneously, intraveously, or intramuscularly.

Claim 51 (Original) The method of claim 41 wherein the pharmaceutically acceptable salt is methanesulfonate salt.

Claim 52 (Cancelled).

Claim 53 (Cancelled).